NFKB2
NFKB2 (Nuclear factor NF-kappa-B p100 subunit) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Colorectal cancer, Skin cancer and 3 more.
Overview
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity.
Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.97, animal model 0.52, genetic association 0.19, somatic mutation 0.97). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Pleural Mesothelioma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NFKB2 (Nuclear factor NF-kappa-B p100 subunit) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Colorectal cancer, Skin cancer and 3 more.
- 1 · What it is
NFKB2 (Nuclear factor NF-kappa-B p100 subunit) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Colorectal cancer, Skin cancer and 3 more.
- 2 · What goes wrong in cancer
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis.
- 3 · How drugs use it
No product in this corpus aims at NFKB2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:7795 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q00653 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000077150 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: colorectal cancer 0.54, melanoma 0.52, skin cancer 0.53 (GraphQL API, CC0)); IntOGen NFKB2 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalisation as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. Location: Nucleus; Cytoplasm (UniProt). Locus 10q24.32 (HGNC).
- Mesothelioma: IntOGen driver in 1 cohort (PLMESO)
- Colorectal cancer: Open Targets association 0.54 with colorectal cancer (MONDO_0005575)
- Skin cancer: Open Targets association 0.53 with skin cancer (MONDO_0002898)
- Diffuse large B-cell lymphoma: IntOGen driver in 1 cohort (DLBCLNOS)
- Pleural mesothelioma: IntOGen driver in 1 cohort (PLMESO)
- Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NFKB2" OR ABSTRACT:"NFKB2" OR TITLE:"nuclear factor kappa B subunit 2" OR ABSTRACT:"nuclear factor kappa B subunit 2" OR TITLE:"Nuclear factor NF-kappa-B p100 subunit" OR ABSTRACT:"Nuclear factor NF-kappa-B p100 subunit" OR TITLE:"LYT-10" OR ABSTRACT:"LYT-10" OR TITLE:"p52" OR ABSTRACT:"p52" OR TITLE:"p105" OR ABSTRACT:"p105") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NFKB2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTRAF7
Shares Pleural mesothelioma, Mesothelioma, Skin cancer (all types), IntOGen.
- TargetFLG
Shares Pleural mesothelioma, Mesothelioma, Skin cancer (all types), IntOGen.
- TargetLATS2
Shares Pleural mesothelioma, Mesothelioma, Skin cancer (all types), IntOGen.
- TargetCYP2C8
Shares Pleural mesothelioma, Mesothelioma, IntOGen, Melanoma.
- TargetNIN
Shares Pleural mesothelioma, Mesothelioma, IntOGen, Colorectal cancer.
- TargetHLA-DQA1
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetPDZD2
Shares Pleural mesothelioma, Mesothelioma, IntOGen.
- TargetPI4KA
Shares Pleural mesothelioma, Mesothelioma, IntOGen.